ClinicalTrials.gg

Prostatic Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 7,051 studies for Prostatic Neoplasms across more than 10 countries. 1,582 are recruiting or about to start. 6,096 of them are mainly about Prostatic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Prostatic Neoplasms, Castration-Resistant too: 7,103 studies, 1,592 open.

ClinicalTrials.gov finds 7,655 studies for Prostatic Neoplasms. How that becomes 7,047 here

This page counts the studies the registry files under Prostatic Neoplasms, and those it files under no condition that list Prostatic Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 7,655Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −52Filed under a narrower condition, counted on its own pageProstatic Neoplasms, Castration-Resistant 52
  3. −146List Prostatic Neoplasms as a condition, but the registry did not file them under itMost often written as “Metastatic Castration-resistant Prostate Cancer” (20), “Castration-resistant Prostate Cancer” (17), and “Prostate Cancer Metastatic” (14). The registry filed them under other conditions only, most often Carcinoma, Non-Small-Cell Lung (32) and Triple Negative Breast Neoplasms (23).
  4. −410Match it another way234 name it in the title, 29 in a keyword, and 147 by a synonym or other text the search reads.
  5. 7,047The count on this page585 of them list Prostatic Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
3,263
Recruiting
1,230
Terminated
669
Active, not recruiting
622
Status unknown
595
Not yet recruiting
297

Phase

Phase 2
2,161
Phase 1
1,224
Phase 3
650
Phase 4
136
Early Phase 1
127

Where

United States
3,596
Canada
712
China
541
France
509
United Kingdom
486
Italy
337

Who develops what

Add Prostatic Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 164 programs from 93 companies, 129 with this as their studies’ main aim; 27 with a live phase 3 study; 37 primary completions in the next 12 months. Compare Novartis, AstraZeneca and Jiangsu HengRui Medicine here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
enzalutamideRecent, repeated
Evidence
  • NCT07908524 · Merck & Co., Inc · Phase 2 · live · background · “Enzalutamide” · registered Oct 2026
  • NCT07871110 · TransThera Sciences (Nanjing), Inc. · Phase 2 · live · comparator · “Enzalutamide 160mg daily (oral)” · registered Oct 2026
  • NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Enzalutamide” · registered Aug 2026
  • NCT07711002 · AstraZeneca · Phase 3 · live · background · “Enzalutamide” · registered Jul 2026
  • NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Enzalutamide” · registered Jun 2026
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized2131 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT07908524 · Merck & Co., Inc · Phase 2 · live · background · “Abiraterone acetate” · registered Oct 2026
  • NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Abiraterone” · registered Aug 2026
  • NCT07711002 · AstraZeneca · Phase 3 · live · background · “Abiraterone” · registered Jul 2026
  • NCT07641855 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Abiraterone” · registered Jun 2026
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Abiraterone” · registered May 2026
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized1829 studies
DocetaxelRecent, repeated
Evidence
  • NCT07908524 · Merck & Co., Inc · Phase 2 · live · comparator · “Docetaxel” · registered Oct 2026
  • NCT07723248 · ORIC Pharmaceuticals · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
  • NCT07632690 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
  • NCT07590934 · AstraZeneca · Phase 2 · live · comparator · “Docetaxel” · registered May 2026
  • NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Docetaxel” · registered Jan 2026
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized1113 studies
PrednisoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Prednisone” · registered Aug 2026
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Prednisone” · registered May 2026
  • NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Prednisone/prednisolone” · registered Jan 2026
  • NCT06952803 · AstraZeneca · Phase 3 · live · background · “Abiraterone + Prednisolone/Prednisone” · registered Apr 2025
  • NCT06925737 · Merck & Co., Inc · Phase 3 · live · comparator · “Prednisone” · registered Apr 2025
Johnson & Johnson11% of its industry studies68 studies
PrednisoloneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07802704 · GlaxoSmithKline · Phase 3 · live · comparator · “Prednisolone” · registered Aug 2026
  • NCT07553988 · R-Pharm · Phase 2 · live · comparator · “Prednisolone” · registered Apr 2026
  • NCT07365995 · BioNTech SE · Phase 3 · live · comparator · “Prednisone/prednisolone” · registered Jan 2026
  • NCT06952803 · AstraZeneca · Phase 3 · live · background · “Abiraterone + Prednisolone/Prednisone” · registered Apr 2025
  • NCT05288166 · Eli Lilly and Company · Phase 3 · live · background · “Prednisone or Prednisolone” · registered Mar 2022
Sanofi15% of its industry studies55 studies
apalutamideRecent, repeated
Evidence
  • NCT07745361 · Monte Rosa Therapeutics, Inc · Phase 2 · live · background · “Apalutamide” · registered Jul 2026
  • NCT07611110 · AstraZeneca · Phase 3 · live · background · “Apalutamide” · registered Apr 2026
  • NCT05422911 · Sun Pharmaceutical Industries Limited · Phase 2 · live · comparator · “Apalutamide” · registered Jun 2022
Johnson & Johnson87% of its industry studiesUS: Johnson & Johnson (FDA 2018)EU: Johnson & Johnson (EMA 2019)33 studies
Antiandrogen TherapyRecent, repeated
Evidence
  • NCT07553988 · R-Pharm · Phase 2 · live · background · “Androgen deprivation therapy (ADT)” · registered Apr 2026
  • NCT06952803 · AstraZeneca · Phase 3 · live · background · “Androgen Deprivation Therapy (ADT)” · registered Apr 2025
  • NCT04108208 · Johnson & Johnson · Phase 4 · background · “Androgen-deprivation Therapy (ADT)” · registered Sep 2019
  • NCT03767244 · Johnson & Johnson · Phase 3 · live · background · “Androgen Deprivation Therapy (ADT)” · registered Dec 2018
  • NCT03641560 · Astellas Pharma Inc · Phase 4 · background · “Androgen deprivation therapy (ADT)” · registered Aug 2018
—22 studies
cabazitaxelRecent, repeated
Evidence
  • NCT07611110 · AstraZeneca · Phase 3 · live · background · “Cabazitaxel” · registered Apr 2026
  • NCT07213674 · Amgen · Phase 3 · live · comparator · “Cabazitaxel” · registered Sep 2025
  • NCT06691984 · Amgen · Phase 3 · live · comparator · “Cabazitaxel” · registered Nov 2024
  • NCT04495179 · AstraZeneca · Phase 2 · background · “Cabazitaxel” · registered Jul 2020
  • NCT01578655 · Achieve Life Sciences · Phase 3 · background · “cabazitaxel” · registered Apr 2012
Sanofi90% of its industry studiesEU: off-patent, 1 generic authorized23 studies
atezolizumabRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
  • NCT05253053 · TransThera Sciences (Nanjing), Inc. · Phase 2 · background · “Combination Product: Atezolizumab” · registered Jan 2022
  • NCT04471727 · Merck & Co., Inc · Phase 2 · live · background · “Atezolizumab” · registered Jul 2020
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)22 studies
darolutamideRecent, repeated
Evidence
  • NCT07871110 · TransThera Sciences (Nanjing), Inc. · Phase 2 · live · comparator · “Darolutamide 600 mg twice daily” · registered Oct 2026
  • NCT07711002 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Jul 2026
  • NCT07611110 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Apr 2026
  • NCT06120491 · AstraZeneca · Phase 3 · live · background · “Darolutamide” · registered Oct 2023
Bayer62% of its industry studiesUS: Bayer (FDA 2019)EU: Bayer (EMA 2020)24 studies
olaparibRecent, repeated
Evidence
  • NCT07641855 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Olaparib” · registered Jun 2026
  • NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
  • NCT04556617 · Opna Bio LLC · Phase 2 · background · “Olaparib” · registered Sep 2020
AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014)22 studies
prednisone acetateRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06136650 · Merck & Co., Inc · Phase 3 · live · comparator · “Prednisone acetate” · registered Nov 2023
  • NCT05405439 · Sino Biopharmaceutical Limited · Phase 2 · background · “prednisone acetate tablets” · registered May 2022
Jiangsu HengRui Medicine Co., Ltd.50% of its industry studies22 studies

41 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
abefolastat tesaroxetan CU-64☆ Track2 live phase-3 studies: NCT06056830, NCT06970847Clarity Pharmaceuticals Ltd
gallium 68 PSMA-11Approved: US☆ Track2 live phase-3 studies: NCT07052214, NCT05847348Telix Pharmaceuticals Limited
mevrometostat☆ Track3 live phase-3 studies: NCT06551324, NCT06629779, NCT07028853Pfizer
rezvilutamide☆ Track2 live phase-3 studies: NCT07241416, NCT03520478Jiangsu HengRui Medicine Co., Ltd.
68-Ga-NYM032☆ Track1 live phase-3 study: NCT07615101Norroy Bioscience Co., LTD

The 5 in phase 3 with the nearest primary completion, of 164 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (37)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 24 Nov 2026 est.STEAP2-targeting Radioconjugate AZD2287 · AstraZeneca · Phase 2 main aimNCT06267729 Study of AZD0754 in Participants With Metastatic Prostate Cancer — primary endpoint: Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs). · 60 enrolled
  • Dec 2026 est.MRT-2359 · Monte Rosa Therapeutics, Inc · Phase 2 main aimNCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients — primary endpoint: Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2D · 174 enrolled
  • Dec 2026 est.HRS-5041 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 main aim+ HRS-5041 tablets, Prednisone Acetate tablets vs Docetaxel+ HRS-5041 tablets, Prednisone Acetate tablets vs HRS-2189NCT06568094 A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer — primary endpoint: Recommended phase II dose (Phase Ib) · 100 enrolled

34 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Prostatic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiandrogens 48 open · Antimitotic agents 17 open · PARP inhibitors 16 open · Immune checkpoint inhibitors 8 open · Tyrosine kinase inhibitors (TKIs) 7 open

Coming up

630studies finish main data collection within a year44 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger. 67 (5%) take children under 18. 0 (0%) are for women only and 1,003 (82%) for men only; 82 (7%) take healthy volunteers.

Recruiting studies that take each age, of 1,230
AgeWomenMen
1017 (1%)64 (5%)
18206 (17%)1,031 (84%)
30218 (18%)1,087 (88%)
40223 (18%)1,162 (94%)
50224 (18%)1,209 (98%)
65226 (18%)1,225 (100%)
75226 (18%)1,208 (98%)
85205 (17%)1,081 (88%)

Across all 7,051 studies, recruiting or not: 7% stop at 75 or younger and 1% at 65; 9% take children; <1% are for women only and 84% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Prostatic Neoplasms studies take

Of 724 phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 143 mo23–68 · 456 studies37 mo20–62 · 212 studies46 mo27–76 · 244 studies
Phase 1/261 mo30–85 · 210 studies52 mo35–… · 96 studies65 mo28–85 · 114 studies
Phase 253 mo34–81 · 724 studies35 mo21–45 · 114 studies57 mo39–86 · 610 studies
Phase 2/3115 mo32–… · 43 studies——
Phase 357 mo31–100 · 265 studies38 mo23–53 · 126 studies99 mo57–144 · 139 studies
Phase 441 mo28–67 · 52 studies——
Interventional, no phase43 mo22–86 · 1,157 studies47 mo16–72 · 57 studies43 mo22–87 · 1,100 studies
Observational60 mo29–141 · 651 studies45 mo24–65 · 109 studies67 mo30–162 · 542 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting19

Show 14 more

Newly registered35

Show 30 more

Studies

Recruiting first, then most recently updated. Showing 50 of 7,051. Browse all 7,051 → or search them.